A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy

Table 4 Pharmacokinetics of artemether–lumefantrine during pregnancy

Publication	Description	Median (range) Day 7 lumefantrine concentration	Median (range) lumefantrine C_max	Lumefantrine exposure	Artemether exposure (AUC_0→8h)
McGready *et al.,* 2006[21]	Pharmacokinetic study of AL in pregnancy using venous plasma samples (n = 13). Results compared with a previous report in non-pregnant adults (n = 17)	384 ng/ml (62–835)*	7340 ng/ml (1,590–15,670)*	Pregnant: 237 μg/ml.h (90% predicted range 75–576)^†, Non-pregnant: 251 μg/ml.h (90% predicted range 79–616)^†	Pregnant, median (90% range): 66.4 ng/ml.h (10.5–264.8), Non-pregnant, mean (SD): 211 ng/ml.h (109)
Tarning *et al.,* 2009[37]	Pharmacokinetic study of AL in pregnancy using capillary plasma samples (n = 103)	Capillary plasma: 391 ng/ml (126–1,600), venous plasma (approx): 310 ng/ml (94–1,364)		AUC_0→∞, median (range): 472 μg/ml.h (119–1,261)
Piola *et al.,* 2010[25]	Open-label, randomized study of AL vs. Q in the 2^nd and 3^rd trimesters, with pharmacokinetic analysis of venous plasma samples (n = 97)	481 ng/ml (15–3,246)

ISSN: 1475-2875